Summary

Global Cervical Cancer Diagnostic Market is valued approximately USD 8.7 billion in 2021 and is anticipated to grow with a healthy growth rate of more than 4.6% over the forecast period 2022-2029. Cervical cancer is a medical condition in which cells in the cervix lining develop into a pre-cancerous mass of cells that eventually develop into tumor tissues. The Cervical Cancer Diagnostic market is expanding because of factors such as rising prevalence of cervical cancer and growing favorable government policies.

Cervical cancers that are typically screened and diagnosed in women are adenocarcinoma and squamous cell carcinoma. Its prevalence has progressively increased during the last few decades. According to the World Health Organization, Cervical cancer is the fourth most common cancer among women globally, with an estimated 604 000 new cases and 342 000 deaths in 2020. About 90% of the new cases and deaths worldwide in 2020 occurred in low- and middle-income countries. Furthermore, two human papillomavirus types (16 and 18) are responsible for nearly 50% of high-grade cervical pre-cancers. Another important component driving space increase is favorable government policies. As per U.S. Department of Health & Human Services, each year in the United States, about 13,000 new cases of cervical cancer are diagnosed and about 4,000 women die of this cancer. Hispanic women have the highest rates of developing cervical cancer, and Black women have the highest rates of dying from cervical cancer. In addition, Roche launched human papillomavirus (HPV) self-sampling solution in countries accepting the CE mark. This new solution enables a patient to privately collect her sample for HPV screening while at a healthcare facility, following instructions provided by a healthcare worker. The clinically validated vaginal sample is analyzed with the Roche Cobas HPV test on a Roche molecular instrument. However, the high cost of Cervical Cancer Diagnostic stifles market growth throughout the forecast period of 2022-2029.

The key regions considered for the Global Cervical Cancer Diagnostic Market study includes Asia Pacific, North America, Europe, Latin America, and Rest of the World. North America dominated the market in terms of revenue, due to increased public awareness of cervical cancer diagnosis. According to the American Cancer Society, in 2023 about 13,960 new cases of invasive cervical cancer will be diagnosed and 4,310 women will die from cervical cancer. Furthermore, Asia Pacific is expected to grow with a highest CAGR during the forecast period, owing to factors such as increase in government initiatives on cancer awareness, and active participation of government and nonprofit organizations in the market space.

Major market player included in this report are:
Siemens Healthcare GmbH
F. Hoffmann-La Roche Ltd
Abbott
Hologic, Inc
Quest Diagnostics Incorporated
Bio-Rad Laboratories, Inc
The Cooper Companies Inc
Seegene Inc
Sysmex Corporation
Guided Therapeutics, Inc
Recent Developments in the Market:
 In November 2021, Hologic, Inc, announced its new ‘Genius Digital Diagnostics System’, which is currently commercially available in Europe. This is a next-generation of cervical cancer screening system that is developed with deep learning-based artificial intelligence (AI) with an advanced volumetric imaging technology in order to help detect cervical cancer cells and pre-cancerous lesions in women.

Global Cervical Cancer Diagnostic Market Report Scope:
Historical Data 2019-2020-2021
Base Year for Estimation 2021
Forecast period 2022-2029
Report Coverage Revenue forecast, Company Ranking, Competitive Landscape, Growth factors, and Trends
Segments Covered Diagnostic Test, End-user, Region
Regional Scope North America; Europe; Asia Pacific; Latin America; Rest of the World
Customization Scope Free report customization (equivalent up to 8 analyst’s working hours) with purchase. Addition or alteration to country, regional & segment scope*




The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within countries involved in the study.

The report also caters detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, it also incorporates potential opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players. The detailed segments and sub-segment of the market are explained below:


by Diagnostic Test
Pap Smear
HPV
Colposcopy
Biopsy & Endocervical Curettage
Other

by End-user
Hospitals
Orthopedic Clinics
Others

By Region:
North America
U.S.
Canada
Europe
UK
Germany
France
Spain
Italy
ROE
Asia Pacific
China
India
Japan
Australia
South Korea
RoAPAC
Latin America
Brazil
Mexico
RoLA
Rest of the World

ページTOPに戻る

Table of Contents

Chapter 1. Executive Summary
1.1. Market Snapshot
1.2. Global & Segmental Market Estimates & Forecasts, 2019-2029 (USD Billion)
1.2.1. Cervical Cancer Diagnostic Market, by Region, 2019-2029 (USD Billion)
1.2.2. Cervical Cancer Diagnostic Market, by Diagnostic Test, 2019-2029 (USD Billion)
1.2.3. Cervical Cancer Diagnostic Market, by End-user, 2019-2029 (USD Billion)
1.3. Key Trends
1.4. Estimation Methodology
1.5. Research Assumption
Chapter 2. Global Cervical Cancer Diagnostic Market Definition and Scope
2.1. Objective of the Study
2.2. Market Definition & Scope
2.2.1. Scope of the Study
2.2.2. Industry Evolution
2.3. Years Considered for the Study
2.4. Currency Conversion Rates
Chapter 3. Global Cervical Cancer Diagnostic Market Dynamics
3.1. Cervical Cancer Diagnostic Market Impact Analysis (2019-2029)
3.1.1. Market Drivers
3.1.1.1. Rising prevalence of cervical cancer
3.1.1.2. Growing favourable government policies
3.1.2. Market Challenges
3.1.2.1. High Cost of Cervical Cancer Diagnostic
3.1.3. Market Opportunities
3.1.3.1. Advancements in R&D activities
Chapter 4. Global Cervical Cancer Diagnostic Market Industry Analysis
4.1. Porter’s 5 Force Model
4.1.1. Bargaining Power of Suppliers
4.1.2. Bargaining Power of Buyers
4.1.3. Threat of New Entrants
4.1.4. Threat of Substitutes
4.1.5. Competitive Rivalry
4.2. Futuristic Approach to Porter’s 5 Force Model (2019-2029)
4.3. PEST Analysis
4.3.1. Political
4.3.2. Economical
4.3.3. Social
4.3.4. Technological
4.4. Top investment opportunity
4.5. Top winning strategies
4.6. Industry Experts Prospective
4.7. Analyst Recommendation & Conclusion
Chapter 5. Risk Assessment: COVID-19 Impact
5.1. Assessment of the overall impact of COVID-19 on the industry
5.2. Pre COVID-19 and post COVID-19 Market scenario
Chapter 6. Global Cervical Cancer Diagnostic Market, by Diagnostic Test
6.1. Market Snapshot
6.2. Global Cervical Cancer Diagnostic Market by Diagnostic Test, Performance - Potential Analysis
6.3. Global Cervical Cancer Diagnostic Market Estimates & Forecasts by Diagnostic Test 2019-2029 (USD Billion)
6.4. Cervical Cancer Diagnostic Market, Sub Segment Analysis
6.4.1. Pap Smear
6.4.2. HPV
6.4.3. Colposcopy
6.4.4. Biopsy & Endocervical Curettage
6.4.5. Other
Chapter 7. Global Cervical Cancer Diagnostic Market, by End-user
7.1. Market Snapshot
7.2. Global Cervical Cancer Diagnostic Market by End-user, Performance - Potential Analysis
7.3. Global Cervical Cancer Diagnostic Market Estimates & Forecasts by End-user 2019-2029 (USD Billion)
7.4. Cervical Cancer Diagnostic Market, Sub Segment Analysis
7.4.1. Hospitals
7.4.2. Orthopaedic Clinics
7.4.3. Others
Chapter 8. Global Cervical Cancer Diagnostic Market, Regional Analysis
8.1. Cervical Cancer Diagnostic Market, Regional Market Snapshot
8.2. North America Cervical Cancer Diagnostic Market
8.2.1. U.S. Cervical Cancer Diagnostic Market
8.2.1.1. Diagnostic Test breakdown estimates & forecasts, 2019-2029
8.2.1.2. End-user breakdown estimates & forecasts, 2019-2029
8.2.2. Canada Cervical Cancer Diagnostic Market
8.3. Europe Cervical Cancer Diagnostic Market Snapshot
8.3.1. U.K. Cervical Cancer Diagnostic Market
8.3.2. Germany Cervical Cancer Diagnostic Market
8.3.3. France Cervical Cancer Diagnostic Market
8.3.4. Spain Cervical Cancer Diagnostic Market
8.3.5. Italy Cervical Cancer Diagnostic Market
8.3.6. Rest of Europe Cervical Cancer Diagnostic Market
8.4. Asia-Pacific Cervical Cancer Diagnostic Market Snapshot
8.4.1. China Cervical Cancer Diagnostic Market
8.4.2. India Cervical Cancer Diagnostic Market
8.4.3. Japan Cervical Cancer Diagnostic Market
8.4.4. Australia Cervical Cancer Diagnostic Market
8.4.5. South Korea Cervical Cancer Diagnostic Market
8.4.6. Rest of Asia Pacific Cervical Cancer Diagnostic Market
8.5. Latin America Cervical Cancer Diagnostic Market Snapshot
8.5.1. Brazil Cervical Cancer Diagnostic Market
8.5.2. Mexico Cervical Cancer Diagnostic Market
8.5.3. Rest of Latin America Cervical Cancer Diagnostic Market
8.6. Rest of The World Cervical Cancer Diagnostic Market

Chapter 9. Competitive Intelligence
9.1. Top Market Strategies
9.2. Company Profiles
9.2.1. Siemens Healthcare GmbH
9.2.1.1. Key Information
9.2.1.2. Overview
9.2.1.3. Financial (Subject to Data Availability)
9.2.1.4. Product Summary
9.2.1.5. Recent Developments
9.2.2. F. Hoffmann-La Roche Ltd
9.2.3. Abbott
9.2.4. Hologic, Inc
9.2.5. Quest Diagnostics Incorporated
9.2.6. Bio-Rad Laboratories, Inc
9.2.7. The Cooper Companies Inc
9.2.8. Seegene Inc
9.2.9. Sysmex Corporation
9.2.10. Guided Therapeutics, Inc

Chapter 10. Research Process
10.1. Research Process
10.1.1. Data Mining
10.1.2. Analysis
10.1.3. Market Estimation
10.1.4. Validation
10.1.5. Publishing
10.2. Research Attributes
10.3. Research Assumption